AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04529343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality mediated upper extremity rehabilitation
Description: Game-based exercise will be applied for different range of motion of the upper extremity. Gamified exercise program consisting of 4 different scenarios will be applied 3 days a week for 6 weeks to the patients in the virtual reality group. A session takes an average of 45 minutes.~Games to be applied;~1. Finger flexion-extension (10 minutes / session)~2. Wrist flexion, extension, ulnar and radial deviation (10 minutes / session)~3. Forearm pronation and supination (10 minutes / session)~4. Elbow flexion-extension-shoulder internal and external rotation (15 minutes / session) will have scenarios controlled with. All patients participating in the study will receive exercise therapy in the form of upper extremity stretching, range of motion, and fine skill training 2 days a week for 6 weeks. Each session takes an average of 45 minutes.
Study NCT04529343 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical exercise therapy for upper extremities
Description: All patients participating in the study will receive exercise therapy in the form of upper extremity stretching, range of motion, and fine skill training 2 days a week for 6 weeks. Each session takes an average of 45 minutes.
Study NCT04529343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical exercise therapy for upper extremities
Description: All patients participating in the study will receive exercise therapy in the form of upper extremity stretching, range of motion, and fine skill training 2 days a week for 6 weeks. Each session takes an average of 45 minutes.
Study NCT03654508 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: ADRB2-genotype guided treatment
Description: This intervention assesses whether ADRB2 genotype-guided treatment leads to better asthma control after 3 months compared to usual care in children who are uncontrolled despite adherent and adequate use of ICS.
Study NCT03654508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Randomisation
Description: In the control arm, children will be randomised over double dose ICS or ICS+LABA instead of treatment according to their genotype.
Study NCT00722956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: 100 mg once daily, 10 days
Study NCT00722956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: one single dose of 40 mg on day 10
Study NCT00913445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: appendicectomy
Description: Wound healing after absorbable and nonabsorbable stitches are compared
Study NCT00708799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Azithromycin on admission - not enrolled in the RCT
Description: One dose of azithromycin prior to inclusion to the RCT
Study NCT02290353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FEATHERS
Description: FEATHERS Device includes a camera (PS3 Eye), 2 modified PS3 Move controllers, and a computer \[2\]. A software is designed to search through the camera feed to find the glowing balls attached to PS3 Move controllers, and changes the position of the computer's mouse cursor based on the balls' position. The participants play simple Facebook games that involve point-and-click by using the Move controllers and moving their arms in space to control the cursor and play games.~During the 8 weeks of intervention, we ask the participants to use the FEATHERS device to play online games (and thus do exercise) on the FEATHERS Facebook app at least 5 days/week, and at least 30 minutes/day. We are interested in seeing how this type of exercise changes the functional clinical scores of the participants.
Study NCT00719680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro20
Study NCT02560272 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Minhai-HIB
Description: 0.5ml, intramuscular
Study NCT02560272 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Act-HIB®
Description: 0.5ml, intramuscular
Study NCT03069157 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lung recruitment maneuver
Description: lung recruitment manoeuvre will be performed in patients using continuous positive airway pressure( CPAP) (30) cm H2O for (40) seconds after induction of anesthesia then patient will be converted to pressure controlled mode again with PEEP 5 cm H2O
Study NCT02905630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: high intensity aerobic interval training
Study NCT00871338 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2197870A
Description: 3 doses given at 2, 3 and 4 months of age
Study NCT00871338 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar™
Description: 3 co-administered doses, intramuscular into right thigh
Study NCT00871338 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar™
Description: 3 co-administered doses, intramuscular into right thigh
Study NCT00871338 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menitorix™
Description: 1 booster dose at 12 months of age
Study NCT00871338 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menitorix™
Description: 1 booster dose at 12 months of age
Study NCT00871338 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediacel™
Description: 3 doses given at 2, 3 and 4 months of age
Study NCT00871338 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menjugate™
Description: 2 doses given at 3 and 4 months of age
Study NCT04685265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anle138b
Description: capsule containing excipient and anle138b
Study NCT04685265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsule containing excipient
Study NCT04137185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thyroid Stimulating Hormone for Injection
Description: rhTSH was dissolved in 1.2 mL of sterile water for injection to obtain a solution containing 0.9 mg/mL rhTSH.
Study NCT04156035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Orally; 300 mg
Study NCT04156035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenously; 0.12 mg/kg during the first minute followed by a continuous infusion of approximately 0.31 mg/kg/h over approx. 40 min
Study NCT04156035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Pretreatment
Description: Lamotrigine Placebo
Study NCT00338325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading program
Description: Reading of children's story/picture books preoperatively
Study NCT01668498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
Study NCT04156035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pretreatment
Description: Lamotrigine Placebo
Study NCT04156035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion
Description: Ketamine Placebo
Study NCT01085370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early psychological intervention
Description: 3 modules: psychoeducation, reconstruction of the trauma, coping skills
Study NCT02641470 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DA9301 (Vaccinium uliginosum extract)
Study NCT02641470 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02037516 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelomyography
Description: quantitative measurement of the train-of-four with the TOF Watch to determine timing of administration of neostigmine and extubation To assure patient flow the time to reversal administration will be limited to approximately 30 minutes after achieving 4 twitches in qualitative monitoring
Study NCT02037516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Neostigmine is used to reverse the effects of neuromuscular blocking agents
Study NCT02037516 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Qualitative Monitor
Description: Qualitative (tactile or visual) assessment of residual neuromuscular paralysis
Study NCT04091880 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine and influenza vaccine
Description: simultaneously administrated with EV71 vaccine and influenza vaccine
Study NCT04091880 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EV71 vaccine
Description: administrated with EV71 vaccine only
Study NCT04091880 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: influenza vaccine
Description: administrated with influenza vaccine only
Study NCT01668498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
Study NCT02212626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotarex S
Study NCT00556855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-DO
Description: topical lotion, once daily (evening), total duration: 4 weeks
Study NCT00556855 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical lotion, once daily (evening), total duration: 4 weeks
Study NCT03696524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tunneled pleural catheter
Description: Placement of a tunneled pleural catheter through the chest wall into the pleural space to drain the patient's chronic pleural effusion. The catheter is an indwelling device that will be drained from home three times per week by nursing care, the patient, or patient's family.
Study NCT04207749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LID015385 contact lenses
Description: Investigational soft contact lenses
Study NCT04207749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A contact lenses
Description: Commercially available soft contact lenses
Study NCT04207749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based cleaning and disinfecting solution
Study NCT04207749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based cleaning and disinfecting solution
Study NCT04637425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ismigen
Description: Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.
Study NCT04637425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched tablets without any active substance.
Study NCT04561908 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transseptal puncture with Brockenbrough-needle
Description: Conventional transseptal puncture with Brockenbrough-needle
Study NCT04561908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microguidewire-assisted transseptal puncture
Description: Microguidewire-assisted transseptal puncture (0.014-inch microguidewire)
Study NCT03761238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molecular Adsorbent Recirculating System
Description: MARS therapy will start within 24-48 h after randomization and be given on 3 consecutive days in sessions of 8-12 h. The patients are observed for 2 days following the last session, with focus on bilirubin INR and signs of encephalopathy, and can thereafter receive 3 additional sessions in case of no or partial response to treatment.
Study NCT04322396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin
Study NCT04322396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine
Study NCT04322396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo Azithromycin
Study NCT04322396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo Hydroxychloroquine
Study NCT03996200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINIject CS627 implant
Description: MINI SO627 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant (CS627) and a single operator delivery tool.~The delivery tool is a single-use tool, designed for inserting the CS627 implant into the suprachoroidal space in the eye.
Study NCT03755141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herzuma
Description: Herzuma + Treatment of Physician's Choice
Study NCT04338711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib modified release (MR)
Description: Single oral 10 mg multi particulate dose of dose of tofacitinib MR with different levels of enteric coating (MR E1, MR E2, and MR E3) in the fasted state. Additionally, the lowest and highest enteric coating levels will also be evaluated in the fed state.~Treatment F: a 10 mg oral dose of tofacitinib IR solution
Study NCT02883816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assessment of lung function
Description: measurement of lung volumes and flow rates of bronchial
Study NCT02147041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGCG(Epigallocatechin Gallate)
Description: 500mg, three times a day, duration:12 weeks
Study NCT04338711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tofacitinib modified release (MR)
Description: Single oral 10 mg multi particulate dose of dose of tofacitinib MR with different levels of enteric coating (MR E1, MR E2, and MR E3) in the fasted state. Additionally, the lowest and highest enteric coating levels will also be evaluated in the fed state.~Treatment F: a 10 mg oral dose of tofacitinib IR solution
Study NCT03160963 — intervention group
Intervention type: OTHER
Intervention: Power Testing
Description: Chair stand, vertical jump, computerized squat
Study NCT00052845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 70 mg/sq m IV infusion over 1 hour Day 2 of ea cycle
Study NCT00052845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estramustine phosphate sodium
Description: 280 mg PO tid Days 1-5 of ea cycle
Study NCT00052845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exisulind
Description: Two 125 mg capsules PO bid Days 1-21 of ea cycle
Study NCT04151147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Concentrated Growth Factor (Test group)
Description: The patients' blood was collected in 9 ml glass tubes and immediately centrifuged to prevent coagulation in special centrifuge device. The CGF program was set up as follows: accelerated for 30 seconds so as to reach 2700 rpm, rotated for 2 minutes, then reduced to 2400 rpm, then rotated again for 4 minutes and accelerated to 2700 rpm, rotated for 4 minutes, then accelerated to 3000 rpm for 3 minutes, and decelerated for 36 seconds to stop. The middle layer in the tube was separated by the ''Buffy coat'' containing the CGFs fibrin gel using forceps and scissor. Then, this fibrin gel was inserted in the extraction cavity.
Study NCT04151147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Concentrated Growth Factor (Control group)
Description: Third molar extraction was performed under local anesthesia. Following the extraction, the socket was sutured and natural healing process was observed. This side was considered as a control group.
Study NCT02958826 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Anonymous questionnaire asking patients about their experiences with surgical lights, surgical smoke, and surgical sounds during their outpatient procedure.
Study NCT01691027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visuo-motor training
Description: Participants will undergo training on three developed software modules on Samsung Galaxy Note Pro tablets to see their effect on low vision rehabilitation
Study NCT02446015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYSTANE® ULTRA Lubricant Eye Drops
Study NCT02446015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYSTANE® ULTRA Lubricant Eye Drops
Study NCT04179799 — intervention group
Intervention type: DEVICE
Intervention: Diaphragm Pacing
Description: Intramuscular stimulation of the diaphragm, or diaphragm pacing' is achieved by laparoscopic placement of stimulation wires into each hemidiaphragm. Phrenic motor points on the diaphragm are mapped to optimize electrode placement. The electrodes are threaded into the diaphragm muscle and wire leads are externalized and attached to a stimulation controller.
Study NCT03761238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment (SMT)
Description: Patient management and standard medical treatment (SMT) as specified in the study protocol.
Study NCT02262702 — intervention group
Intervention type: DRUG
Intervention: Paracetamol 665 mg
Description: Paracetamol 665 mg tablet
Study NCT02262702 — intervention group
Intervention type: DRUG
Intervention: Paracetamol 500 mg
Description: Paracetamol 500 mg tablet
Study NCT02581215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX:~* Oxaliplatin 85 mg/m2 over 2-4 hours~* Irinotecan 165 mg/m2 over 90 minutes~* 5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.
Study NCT02581215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX:~* Oxaliplatin 85 mg/m2 over 2-4 hours~* Irinotecan 165 mg/m2 over 90 minutes~* 5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.
Study NCT02581215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks.
Study NCT02581215 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion with volume calculated as if it were ramucirumab every 2 weeks.
Study NCT02277925 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polytetrafluoroethylene
Description: Suture used to attach mesh during sacral colpopexy surgery
Study NCT02277925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polydioxanone
Description: Suture used to attach mesh during sacral colpopexy surgery
Study NCT00705367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion, Intravenous, single dose, Day 1
Study NCT00705367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Infusion, Intravenous, 30mg/kg, single dose, Day 1
Study NCT00705367 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Abatacept
Description: Infusion, intravenous, 10 mg/kg, administered on Days 15 and 29 followed by doses every 4 weeks until the end of the study
Study NCT00328458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO906 (epothilone B)
Study NCT00491582 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Growth hormone replacement therapy in growth hormone deficient patients only.
Description: Genotropin once/daily sc., titration scheme according to the consensus guidelines of the GH and IGF-research society Duration: 6 months
Study NCT04064762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paired Vagus Nerve Stimulation
Description: Stimulation of the vagus nerve that is paired with Prolonged Exposure Therapy.
Study NCT02317848 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: polygraphy and ECG
Description: polygraphy and ECG during hospitalisation for acute heart failure to see Persistence of the severity of SAS after 2 months
Study NCT01610336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: During Phase Ib, INC280 was taken at escalating doses. During Phase II part, INC280 was taken at recommended Phase II dose.
Study NCT01610336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250 mg taken once daily
Study NCT02139865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 30% 1RM
Description: Participant exercises using a protocol tailored at 30% of their 1RM
Study NCT02139865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 80% 1RM
Description: Participant exercises using a protocol tailored at 80% of their 1RM
Study NCT01928901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of Sinupret
Study NCT01928901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: administration of Sinupret